Reports
Sale
Type 1 Diabetes Market Size, Trends, Analysis, Forecast: By Insulin Analog: Rapid-Acting Insulin, Short-Acting Insulin, Long-Acting Insulin; By Product Type: Injections/IV, Inhaled insulin; By Route of Administration: Parenteral (Subcutaneous, Intravenous), Oral; By End User: Hospitals, Others; Regional Analysis; Supplier Landscape; 2024-2032
Type 1 Diabetes Market Outlook
The type 1 diabetes market size was valued at USD 7.9 billion in 2023, driven by the increasing prevalence of diabetes across the 7 major markets. The market size is anticipated to grow at a CAGR of 6.8% during the forecast period of 2024-2032 to achieve a value of USD 15.3 billion by 2032.
Type 1 Diabetes: Introduction
Type 1 diabetes is a medical condition that arises from insufficient insulin production by the pancreas in the human body. Insulin is a crucial hormone that supports the entry of sugar (glucose) into cells, enabling the generation of energy. In the absence of adequate insulin, glucose accumulates in the bloodstream. Formerly recognized as juvenile diabetes or insulin-dependent diabetes, type 1 diabetes is not limited to a specific age group and can manifest in individuals of all ages. Recognizable symptoms of type 1 diabetes include frequent urination, persistent thirst, continuous hunger, unexplained weight loss, alterations in vision, and persistent fatigue.
Type 1 Diabetes Market Analysis
The market for diabetes treatment is rapidly growing, and companies are seeking opportunities to create innovative solutions that will lead to better patient outcomes. The treatment landscape for type 1 diabetes has recently undergone significant developments that are expected to have a major impact on the market.
The FDA's approval of Lantidra, a new therapy derived from deceased donor pancreatic cells, marks a major advancement in the field. This allogeneic pancreatic islet cellular therapy is designed to help individuals with type 1 diabetes who are struggling to maintain healthy blood sugar levels despite intensive management efforts. The use of deceased donor cells in this innovative approach represents a paradigm shift in diabetes therapeutics.
In addition, the recent financial sponsorship of Amsterdam-based start-up, Advanced Microbiome Interventions, with a 300,000 Euro (USD 3,28,398) convertible loan from Innovatiefonds Noord-Holland, highlights the growing interest and investment in developing treatments for type 1 diabetes. This financial support is expected to propel AMI's research efforts, potentially leading to novel therapeutic interventions. These actions and shifting interests toward the treatment of type 1 diabetes are expected to bolster the type 1 diabetes market growth.
Furthermore, Sanofi's strategic acquisition of Provention Bio, Inc. for approximately USD 2.9 billion is poised to reshape the landscape of type 1 diabetes treatments. This move strengthens Sanofi's core asset portfolio with TZIELD (teplizumab-mzwv), a first-in-class therapy that has been proven to delay the onset of Stage 3 type 1 diabetes. The acquisition aligns with Sanofi's strategic focus on differentiated products and represents a significant step towards intercepting and preventing immune-mediated diseases, including type 1 diabetes. These transformative developments indicate a promising era of innovation and investment in the type 1 diabetes market, which is expected to lead to improved outcomes for individuals managing this chronic condition and boost market growth.
Type 1 Diabetes Market Segmentations
Market Breakup by Insulin Analog
- Rapid-Acting Insulin
- Short-Acting Insulin
- Long-Acting Insulin
Market Breakup by Mode of Product Type
- Injections/IV
- Inhaled insulin
Market Breakup by Route of Administration
- Parenteral (Subcutaneous, Intravenous)
- Oral
Market Breakup by End User
- Hospital
- Research Institutes
- Home Care
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Type 1 Diabetes Market Overview
The market is expected to witness significant growth in the forecast period, propelled by technological advancements in remote blood glucose monitoring devices. These innovations are expected to enhance the management of Type 1 diabetes, providing patients with more accessible and efficient means of monitoring their blood glucose levels. The market is also driven by strategic initiatives such as acquisitions, partnerships, and collaborations among key industry players. These efforts aim to foster innovation, improve treatment options, expand the reach of diabetes management solutions, and further boost the type 1 diabetes market growth.
Geographically, the United States has been leading the market, boasting the largest revenue share. The prevalence of Type 1 diabetes, particularly among children and adolescents, has contributed to this dominance. The active involvement of major industry players in research and development activities further fuels market growth in North America.
Type 1 Diabetes Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Eli Lilly
- Pfizer
- Stryker Corporation
- Abbott Laboratories
- DiaVasc, Inc.
- Biodel, Inc.
- Sanofi
- Merck
- Astellas Pharma
- Mankind Corporation
- Biodel, Inc,
- Macrogenics
- DiaVacs, Inc.
- Novo Nordisk
- Braun Melsungen
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Insulin Analog |
|
| Breakup by Product Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Patient Profile
3.1 Patient Profile Overview
3.2 Patient Psychology and Emotional Impact Factors
3.3 Risk Assessment and Treatment Success Rate
4 Type 1 Diabetes Epidemiology Analysis – 7MM
4.1 7MM Epidemiology Scenario Overview (2017-2032)
4.2 United States Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3 EU-4 and United Kingdom Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.1 Germany Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.2 France Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.3 Italy Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.4 Spain Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.3.5 United Kingdom Type 1 Diabetes Epidemiology Forecast (2017-2032)
4.4 Japan Type 1 Diabetes Epidemiology Forecast (2017-2032)
5 Type 1 Diabetes Market Overview – 7MM
5.1 Type 1 Diabetes Market Historical Value (2017-2023)
5.2 Type 1 Diabetes Market Forecast Value (2024-2032)
6 Type 1 Diabetes Market Landscape – 7MM
6.1 Type 1 Diabetes: Developers Landscape
6.1.1 Analysis by Year of Establishment
6.1.2 Analysis by Company Size
6.1.3 Analysis by Region
6.2 Type 1 Diabetes: Product Landscape
6.2.1 Analysis by Type
7 Analysis by Technology Type 1 Diabetes Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Cost of Treatment
9 Type 1 Diabetes Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Type 1 Diabetes Market Segmentation – 7MM
10.1 Type 1 Diabetes Market by Insulin Analog
10.1.1 Market Overview
10.1.2 Rapid-Acting Insulin
10.1.3 Short-Acting Insulin
10.1.4 Long-Acting Insulin
10.2 Type 1 Diabetes Market by Product Type
10.2.1 Market Overview
10.2.2 Injections/IV
10.2.3 Inhaled insulin
10.3 Type 1 Diabetes Market by Route of Administration
10.3.1 Market Overview
10.3.2 Parenteral (Subcutaneous, Intravenous)
10.3.3 Oral
10.4 Type 1 Diabetes Market by End User
10.4.1 Market Overview
10.4.2 Hospitals
10.4.3 Research Institutes
10.4.4 Home Care
10.5 Type 1 Diabetes Market by Region
10.5.1 Market Overview
10.5.2 United States
10.5.3 EU-4 and the United Kingdom
10.5.3.1 Germany
10.5.3.2 France
10.5.3.3 Italy
10.5.3.4 Spain
10.5.3.5 United Kingdom
10.5.4 Japan
11 United States Type 1 Diabetes Market
11.1 Type 1 Diabetes Market Historical Value (2017-2023)
11.2 Type 1 Diabetes Market Forecast Value (2024-2032)
11.3 Type 1 Diabetes Market by Disease Type
11.4 Type 1 Diabetes Market by Age group
12 EU-4 and United Kingdom Type 1 Diabetes Market
12.1 Type 1 Diabetes Market Historical Value (2017-2023)
12.2 Type 1 Diabetes Market Forecast Value (2024-2032)
12.3 Germany Type 1 Diabetes Market Overview
12.3.1 Type 1 Diabetes Market by Disease Type
12.3.2 Type 1 Diabetes Market by Age group
12.4 France Type 1 Diabetes Market Overview
12.4.1 Type 1 Diabetes Market by Disease Type
12.4.2 Type 1 Diabetes Market by Age group
12.5 Italy Type 1 Diabetes Market Overview
12.5.1 Type 1 Diabetes Market by Disease Type
12.5.2 Type 1 Diabetes Market by Age group
12.6 Spain Type 1 Diabetes Market Overview
12.6.1 Type 1 Diabetes Market by Disease Type
12.6.2 Type 1 Diabetes Market by Age group
12.7 United Kingdom Type 1 Diabetes Market Overview
12.7.1 Type 1 Diabetes Market by Disease Type
12.7.2 Type 1 Diabetes Market by Age group
13 Japan Type 1 Diabetes Market
13.1 Type 1 Diabetes Market Historical Value (2017-2023)
13.2 Type 1 Diabetes Market Forecast Value (2024-2032)
13.2.1 Type 1 Diabetes Market by Disease Type
13.2.2 Type 1 Diabetes Market by Age group
14 Regulatory Framework
14.1 Regulatory Overview
14.1.1 US FDA
14.1.2 EU EMA
14.1.3 INDIA CDSCO
14.1.4 JAPAN PMDA
14.1.5 Others
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding and Investment Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Eli Lilly
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisitions
20.1.5 Certifications
20.2 Pfizer
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisitions
20.2.5 Certifications
20.3 Stryker Corporation
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisitions
20.3.5 Certifications
20.4 Abbott Laboratories
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisitions
20.4.5 Certifications
20.5 DiaVasc, Inc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisitions
20.5.5 Certifications
20.6 Biodel, Inc.
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisitions
20.6.5 Certifications
20.7 Sanofi
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisitions
20.7.5 Certifications
20.8 Merck
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisitions
20.8.5 Certifications
20.9 Astellas Pharma
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisitions
20.9.5 Certifications
20.10 Mankind Corporation
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisitions
20.10.5 Certifications
20.11 Biodel, Inc,
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisitions
20.11.5 Certifications
20.12 Macrogenics
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisitions
20.12.5 Certifications
20.13 DiaVacs, Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisitions
20.13.5 Certifications
20.14 Novo Nordisk
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisitions
20.14.5 Certifications
20.15 Braun Melsungen
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisitions
20.15.5 Certifications
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 7.9 billion in 2023, driven by the increased diabetes patients.
The market is anticipated to grow at a CAGR of 6.8% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.3 billion by 2032.
The market growth is driven by the rising technological advancements in remote blood glucose monitoring devices.
The increasing focus of key players on developing innovative solutions and companies investing increasingly in the market is a major trend.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 consists of Germany, France, Italy, and Spain.
Different types of insulin analogs include rapid-acting insulin, short-acting insulin, and long-acting insulin.
Different products include injections/IV and inhaled insulin.
The route of administration includes parenteral (subcutaneous, intravenous) and oral.
The end users in the market include hospitals, research institutes, and home care.
Key players involved in the market are Eli Lilly, Pfizer, Stryker Corporation, Abbott Laboratories, DiaVasc, Inc., Biodel, Inc., Sanofi, Merck, Astellas Pharma, Mankind Corporation, Biodel, Inc, Macrogenics, DiaVacs, Inc., Novo Nordisk, and Braun Melsungen.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER